April Breyer Menon, Author at Venable's BiologicsHQ

Keytruda Qlex™ Updates: PTAB Finds Additional Halozyme PH20 Patent Unpatentable in Final Written Decision

by April Breyer Menon | Jun 11, 2026

On June 8, 2026, the Patent Trial and Appeal Board (“PTAB”) issued a Final Written Decision (“FWD”) in PGR2025-00004 finding all remaining challenged claims of Halozyme’s U.S. Patent No. 12,018,298 (“the ’298 patent”) unpatentable. The ’298 patent was challenged...

Supreme Court Clarifies Standard for Pleading Inducement of Patent Infringement in Hikma v. Amarin

by April Breyer Menon | Jun 10, 2026

On June 4, 2026, a unanimous Supreme Court in Hikma Pharms. USA Inc. v. Amarin Pharma, Inc., No. 24-889, clarified the standard for pleading induced patent infringement under 35 U.S.C. § 271(b). Although Hikma dealt specifically with an inducement claim against a...

aBLA Resubmissions: Xbrane’s Xlucane (ranibizumab) and Alvotech’s AVT05 (golimumab) and AVT06 (aflibercept)

by April Breyer Menon | Jun 6, 2026

On June 3, 2026, Xbrane announced the resubmission of its aBLA for Xlucane (ranibizumab), a proposed biosimilar of Genentech’s Lucentis® (ranibizumab) after receiving a second Complete Response Letter (CRL) from the FDA in October 2025. Xbrane previously submitted...

FDA Approves Lupin’s Ranluspec™ (ranibizumab-hkdz) as Fourth Interchangeable Biosimilar of Lucentis®

by April Breyer Menon | Jun 4, 2026

On June 2, 2026, the FDA approved Lupin’s Ranluspec™ (ranibizumab-hkdz) as the fourth interchangeable biosimilar of Genentech’s Lucentis® (ranibizumab). According to Lupin’s press release, this is the first interchangeable ranibizumab biosimilar to be approved...

Amneal and Kashiv File First Xolair® (omalizumab) IPR

by April Breyer Menon | May 28, 2026

On May 26, 2026, Amneal and Kashiv filed IPR2026-00260 challenging Genentech’s U.S. Patent No. 12,030,959, which claims methods for treating food allergies in pediatric patients using omalizumab. The Petition challenges claims 1, 3, 5, 17-18 and 22-24 as anticipated...

« Older Entries

Next Entries »

Methodology

Information contained in the Venable BiologicsHQ database relates to FDA-approved drug products listed in the CDER Purple Book or on the FDA website (www.fda.gov). Information relating to FDA licensed products, FDA-approved indications, and aBLA and 505(b)(2) applications is obtained from public sources including the U.S. FDA website (www.fda.gov). Information relating to litigations is given only for cases active from January 31, 2010 onward. Information relating to foreign biosimilar / biologics follow-on products approved in Australia, Canada, the E.U., Japan and South Korea is from public sources. Statistics graphics are compiled from information contained in the Venable BiologicsHQ database.

Disclaimer

The individuals who maintain this site work for Venable LLP. The information, comments and links posted on this site do not constitute legal advice. No attorney-client relationship has been or will be formed by any communication(s) to, from or with the site and/or the author. For legal advice, contact an attorney at Venable LLP or an attorney actively practicing in your jurisdiction. Do not send any confidential or privileged information to the author; neither Venable LLP nor the author will assume any liability or responsibility for it. If you send any information, documents or materials to the site, you give permission for the author to include them on or in the site. No information, documents or materials you send to the site will be considered confidential or privileged by Venable LLP or its lawyers. Also, no such information, documents or materials will be returned to you. All decisions relating to the content belong to the author.